Haiping Jiang

机构：First Affiliated Hospital of Jinan University, First Affiliated Hospital Zhejiang University · ORCID：0000-0002-8786-4981

发表论文 82 篇 · 总被引 2304 次 · h-index 23

代表论文

• Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study (2023 · The Lancet Oncology · 被引 211)
• Bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 in advanced solid tumors: a dose-escalation, dose-expansion, and clinical-expansion phase 1 trial (2022 · BMC Medicine · 被引 86)
• Heterogeneity and Adjuvant Therapeutic Approaches in MSI-H/dMMR Resectable Gastric Cancer: Emerging Trends in Immunotherapy (2023 · Annals of Surgical Oncology · 被引 32)
• Association of inflammatory markers with survival in patients with advanced gastric cancer treated with immune checkpoint inhibitors combined with chemotherapy as first line treatment (2022 · Frontiers in Oncology · 被引 26)
• In vitro study of piwi interaction RNA-31106 promoting breast carcinogenesis by regulating METTL3-mediated m6A RNA methylation (2023 · Translational Cancer Research · 被引 20)
• Binaphthyl-based chiral covalent organic frameworks for chiral drug separation (2024 · Chemical Communications · 被引 17)